As Big Pharma struggles through an endless cycle of market churn, a strategic question is whether the concept of an "emerging market" is a dated one. Many of these markets are no longer justemerging, but instead are firmly established, with the C-suite placing big bets on them as growth centers against diminished earnings over the next few years from the old mainstay markets of the US, Europe, and Japan.....
Consultoria especializada em GMP/BPF para indústrias voltadas a Ciências da Vida!
Nenhum comentário:
Postar um comentário